The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer

Emanuela Anastasi, Teresa Granato, Renato Falzarano, Paola Storelli, Adele Ticino, Luigi Frati, Pierluigi Benedetti Panici, Maria Grazia Porpora

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Endometriosis is frequently associated with high levels of CA125. This marker is therefore not useful for discriminating ovarian endometrioma from ovarian malignancy. The aim of this study was to establish a panel of complementary biomarkers that could be helpful in the differential diagnosis between ovarian endometriosis or other ovarian benign masses and ovarian cancer. Methods. Blood samples from 50 healthy women, 17 patients with benign ovarian tumors, 57 patients with ovarian endometrioma and 39 patients with ovarian cancer were analyzed and serum values were measured for the following biomarkers: CA125, HE4 and CA72-4. Results: Serum CA125 concentration was elevated in both patients with ovarian endometriosis and ovarian cancer but not in patients with other benign ovarian masses. HE4 was never increased in patients with endometriosis or benign masses whereas it was significantly higher in all patients with ovarian cancer (p <0.05). A marked difference in CA72-4 values was observed between women with ovarian cancer (67%) and those with endometriosis (p <0.05). Conclusions: The results of the study suggest that HE4 and CA72-4 determination is the best approach to confirm the benign nature of ovarian endometrioma in women with high CA125 levels.

Original languageEnglish
Article number44
JournalJournal of Ovarian Research
Volume6
Issue number1
DOIs
Publication statusPublished - 2013

Keywords

  • Adnexal mass
  • CA125
  • CA72-4
  • HE4
  • Ovarian cancer
  • Ovarian endometrioma
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this